Everything below concerns somatotroph. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-24. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
In 1993, the first success of an mRNA vaccine was reported in mice, by using liposome-encapsulated IVT mRNA which is encoding the nucleoprotein of influenza that induced virus-specific T cells. Then, IVT mRNA was formulated with synthetic lipid nanoparticles and it induced protective antibody responses against the respiratory syncytial virus(RSV) and influenza virus in mice. There are a few different types of IVT mRNA-based vaccine development for infectious diseases. One of the successful types is using self-amplifying IVT mRNA that has sequences of positive-stranded RNA viruses. It was originally developed for a flavivirus and it was workable with intradermal injection. One of the other ways is injecting a two-component vaccine which is containing an mRNA adjuvant and naked IVT mRNA encoding influenza hemagglutinin antigen only or in combination with neuraminidase encoding IVT mRNA. For example, for the HIV treatment, vaccines are using DCs transfected with IVT mRNA that is encoding HIV proteins. There are a few phase I and II clinical trials using IVT mRNA encoding combinations and it shows that antigen-specific CD8+ and CD4+ T cell responses can be induced. However, no antiviral effects have been observed in the clinical trial. One of the other mRNA vaccines is for COVID-19. The Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) outbreaks in December 2019 and spread all over the world, causing a pandemic of respiratory illness designated coronavirus disease 2019 (COVID-19).
King Crimson were an English progressive rock band formed in London in 1968. Pioneered by guitarist and primary composer Robert Fripp—the group's sole constant member throughout their history—the band are widely regarded as a foundational catalyst of the progressive rock movement. They drew inspiration from an expansive array of musical styles, incorporating elements of classical, jazz, folk, heavy metal, gamelan, post-punk, industrial, and experimental music. Beyond shaping contemporaries such as Yes and Genesis, King Crimson's genre-spanning innovations have exerted a lasting influence on subsequent generations of alternative rock, metal, and math rock artists, earning the band a enduring global cult following. The band was initially formed by Fripp alongside Michael Giles, Greg Lake, Ian McDonald, and lyricist Peter Sinfield. Their debut album, In the Court of the Crimson King (1969), achieved immediate critical and commercial success, and is widely cited by music historians as a definitive cornerstone of progressive rock. Following the rapid dissolution of the original line-up, the group endured a period of personnel instability, releasing In the Wake of Poseidon (1970), Lizard (1970), and Islands (1971). In 1972, Fripp refashioned the band's direction by recruiting Bill Bruford, John Wetton, David Cross, and Jamie Muir, alongside lyricist Richard Palmer-James.
Third, the EU is formally not enabled to legislate on collective bargaining, although the EU, with all member states, is bound by the jurisprudence of the European Court of Human Rights on freedom of association. In Wilson and Palmer v United Kingdom the Court held that any detriment for membership of a trade union was incompatible with article 11, and in Demir and Baykara v Turkey the Court held "the right to bargain collectively with the employer has, in principle, become one of the essential elements" of article 11. This approach, which includes affirmation of the fundamental right to strike in all democratic member states, has been seen as lying in tension with some of the Court of Justice's previous case law, notably ITWF v Viking Line ABP and Laval Un Partneri Ltd v Svenska Byggnadsarbetareforbundet. These controversial decisions, quickly disapproved by legislative measures, suggested the fundamental right of workers to take collective action was subordinate to business freedom to establish and provide services. More positively, the Information and Consultation Directive 2002 requires that workplaces with over 20 or 50 staff have the right to set up elected work councils with a range of binding rights, the European Works Council Directive 2009 enables work councils transnationally, and the Employee Involvement Directive 2001 requires representation of workers on company boards in some European Companies.
== Diagnosis == While heterotopic bone growth can begin spontaneously in FOP patients, Eastlack, like most patients, first experienced a triggered proliferation due to an illness or injury. When he was three or four years old, in 1937, while playing with his sister Helene, on a local street, a car hit him and injured his leg. He was taken to the hospital where his leg was put in a cast before returning home. The fracture never set properly, and when the cast was removed months later, his leg was painfully swollen with a high amount of inflammation. No further action was taken and shortly after, Eastlack began to experience his first set of abnormal bone growths. His hips and knees had become difficult to move. When he was taken to the hospital with this concern, the doctor took X-rays in which the bony deposits on his thigh muscles were revealed. The doctors were not able to diagnose his condition having seen this, and it continued to progress in the anatomically characteristic manner that FOP does. Eastlack soon suffered flare-ups along his back, neck, and chest. In attempts to diagnose and treat Eastlack's condition, the doctors ordered biopsies and performed a total of 11 surgical procedures to remove excess and heterotopic ossification, such as that on his thigh muscles. However, Eastlack's condition was aggravated by such procedures and the bone plates returned thicker and more predominant. It was 1938, the year after the incident, when he was finally diagnosed with myositis ossificans progressiva, which is now known as fibrodysplasia ossificans progressiva (FOP).
Sources: en.wikipedia.org
In oncology, in situ is applied in the context of carcinoma in situ (CIS), a term describing abnormal cells confined to their original location without invasion of surrounding tissue. The earliest known use of the term dates back to 1932 in the writing of U.S. surgical pathologist Albert C. Broders, who introduced both the term and the concept. The concept of CIS was initially controversial. CIS is a critical term in early cancer diagnosis, as it signifies a non-invasive stage, allowing for more targeted interventions such as localized excision or monitoring—before potential progression to invasive cancer. Melanoma in situ is an early, localized form of melanoma (a type of malignant skin cancer). In this stage, the cancerous melanocytes (the pigment-producing cells that give skin its color) are confined to the epidermis, the outermost layer of the skin; the melanoma has not yet penetrated into the deeper dermal layers or metastasized to other parts of the body. Beyond oncology, in situ is used in fields where maintaining natural anatomical or physiological positions is essential. In orthopedic surgery, the term refers to procedures that preserve the natural alignment or position of bones or joints. For example, orthopedic plates or screws may be placed without altering the bone's original structure, as in "[the patient] was treated operatively with an in situ cannulated hip screw fixation". In cardiothoracic surgery, in situ often describes techniques where blood vessels are utilized in their original anatomical position for surgical purposes.
=== 1.3 === DisplayPort version 1.3 was approved on 15 September 2014. This standard increases overall transmission bandwidth to 32.4 Gbit/s with the new HBR3 mode featuring 8.1 Gbit/s per lane (up from 5.4 Gbit/s with HBR2 in version 1.2), for a total data throughput of 25.92 Gbit/s after factoring in 8b/10b encoding overhead. This bandwidth is enough for a 4K UHD display (3840 × 2160) at 120 Hz with 24 bit/px RGB color, a 5K display (5120 × 2880) at 60 Hz with 30 bit/px RGB color, or an 8K UHD display (7680 × 4320) at 30 Hz with 24 bit/px RGB color. Using Multi-Stream Transport (MST), a DisplayPort port can drive two 4K UHD (3840 × 2160) displays at 60 Hz, or up to four WQXGA (2560 × 1600) displays at 60 Hz with 24 bit/px RGB color. The new standard includes mandatory Dual-mode for DVI and HDMI adapters, implementing the HDMI 2.0 standard and HDCP 2.2 content protection. The Thunderbolt 3 connection standard was originally to include DisplayPort 1.3 capability, but the final release ended up with only version 1.2 for Intel 6000 Series Thunderbolt 3 Controllers. Later Intel 7000 Series Thunderbolt 3 controllers support DisplayPort 1.4 capability including HDR. The VESA's Adaptive Sync feature in DisplayPort version 1.3 remains an optional part of the specification.
=== Drug withdrawal === Phenobarbital is sometimes used for alcohol detoxification and benzodiazepine detoxification for its sedative and anticonvulsant properties. The benzodiazepines chlordiazepoxide (Librium) and oxazepam (Serax) have largely replaced phenobarbital for detoxification.
== Sources == Samuel W. Mitcham (2007). German Order of Battle. Volume Two: 291st–999th Infantry Divisions, Named Infantry Divisions, and Special Divisions in WWII. Stackpole Books. ISBN 978-0-8117-3437-0, p. 148–149. Georg Tessin: Verbände und Truppen der deutschen Wehrmacht und Waffen-SS im Zweiten Weltkrieg 1939–1945. Volume 11. Die Landstreitkräfte 501–630. Biblio-Verlag, Bissendorf 1975, ISBN 3-7648-1181-1, p. 128.
=== Spectrum of susceptibility === Doxycycline has been used successfully to treat sexually transmitted, respiratory, and eye infections. Representative pathogenic genera include Chlamydia, Streptococcus, Ureaplasma, Mycoplasma, and others. The minimum inhibitory concentration for a few medically significant microorganisms are:
Sources: en.wikipedia.org
== Side effects == Compared to other tricyclic antidepressants, it produces significantly fewer cardiovascular, anticholinergic (like dry mouth or constipation), sedative and appetite-stimulating effects. Unlike other tricyclic antidepressants, tianeptine does not affect heart function. μ-Opioid receptor agonists (Opioid) can sometimes induce euphoria, as does tianeptine, occasionally, at high doses, well above the normal therapeutic range (see § Recreational use below) which makes them prone for abuse. As such, it is not recommended to use Tianeptine for patients with history of any substance abuse, especially in opioid use disorders. Tianeptine can also cause severe withdrawal symptoms after prolonged use at high doses which should prompt extreme caution when stopping treatment.
=== Trump tariffs === In January 2025, Ford began to state that he would need a "clear mandate" from voters to respond to the tariffs on Canadian imports to the United States threatened by new President Donald Trump, calling the 2025 Ontario general election. Ford was caught on video saying that on the day of the 2024 U.S. presidential election he was "100% happy" that Trump won, until Trump threatened tariffs on Canada. During the election campaign, his party promised to invest $10 billion in cash-flow support for Ontario employers, $3 billion in payroll tax and premium relief, $120 million to support approximately 18,000 bars and restaurants, $40 million for a new Trade-Impacted Communities Program, $300 million to expand the Ontario Made Manufacturing Investment Tax Credit, and $600 million for the Invest Ontario Fund. Ford also advised the new Prime Minister, Mark Carney, on strategies to mitigate the trade war, and appeared on multiple American news shows. After being re-elected to a third term in 2025, the government passed The Protect Ontario Through Free Trade Within Canada Act, 2025, which removed internal barriers to trade in goods, among other changes. In October 2025, Ford launched an ad campaign in the United States criticizing the tariffs. The ad featured a clip of Ronald Reagan from 1987 warning against the economic impact of trade wars.
=== Regulatory macrophages === Glucocorticoids can contribute to the development of regulatory macrophages. These macrophages produce Interleukin 10 and inhibit immune system response (See below for Effect on cancer). Tumor-associated macrophages may contain a large population of regulatory macrophages.
South Korean intelligence officials also said that the North Korean government had locked down Pyongyang, and had refused to accept 110,000 tons of rice from China for fear of letting the virus into the country. Expatriates in North Korea became concerned about getting treatment for COVID-19, since the North Korean medical system was limited, and it was difficult to seek treatment in China due to travel restrictions. According to NK News, on 22 September, the crew of a North Korean patrol boat killed a South Korean fisheries officer whom they encountered off their coast, and then torched his flotation device in compliance with COVID-19 emergency orders. Kim apologized to South Korea for the incident. In October, North Korean media said that the world was looking at North Korea with envy because of its virus-free status, but at the same time warned against complacency. In the same month, there was a spike in people tested and quarantined, possibly related to celebrations on 10 October. During these celebrations, Kim Jong Un criticised himself and the leadership of the Workers' Party of Korea for falling short during the COVID-19 pandemic. In November 2020, Daily NK reported that there had been a spike of residents in quarantine facilities with COVID-19 symptoms, and that at least 80,000 non-military residents had been quarantined in total by then, although the country continued to maintain that it did not have any confirmed cases.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.